Sellas Life Sciences, a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, provided an update on the ongoing Phase 3 REGAL trial evaluating GPS as a potential maintenance therapy in patients with AML after second complete remission. Our proprietary real time alert services picked up SLS's unusual stock and option volume Monday morning. Depending on your favorite momentum indicator several...